Skip to main content

Nasdaq Markets

Is BigBear.ai Stock a Buy Now?

2 years 6 months ago
The tech world is a competitive landscape. Three companies vying for investor attention in the even more heated subsector of data analytics are Snowflake (NYSE: SNOW), Palantir (NYSE: PLTR), and BigBear.ai (NYSE: BBAI). Snowflake and Palantir are established players, but BigBear.
The Motley Fool

Here's How Getting Married Affects Your Social Security Benefits

2 years 6 months ago
Getting married is a personal milestone for many Americans, but it also has a huge effect on your finances, now and far into the future. For many couples tying the knot, Social Security and retirement probably aren't on their minds. But it's useful to have at least a basic unders
The Motley Fool

Is It Too Late to Buy Meta Platforms Stock?

2 years 6 months ago
Many tech stocks surged over the past year thanks to factors such as the artificial intelligence (AI) boom. One stock that more than doubled in that time is Meta Platforms (NASDAQ: META).
The Motley Fool

3 Secrets of 401(k) Millionaires

2 years 6 months ago
If you want to retire a millionaire, your 401(k) can be an incredibly powerful tool to get you there. Indeed, if you use it well, you might even be able to reach millionaire status just from your 401(k) plan on its own.Yet as powerful as a well-invested 401(k) plan can be, it's n
The Motley Fool

Is Real Estate a Solid Investment?

2 years 6 months ago
Real estate investing was once an exclusive club of the wealthy. They were the only ones with the access and finances to invest in income-producing commercial real estate. That gave wealthy investors an advantage because they could use real estate to build and sustain their wealt
The Motley Fool

Is Viking Therapeutics Stock a Millionaire Maker?

2 years 6 months ago
There's no shortage of hype and excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock these days. The company has a promising weight loss drug candidate in its pipeline at a time when many healthcare businesses are eager to get a piece of that massive market. This year
The Motley Fool

FDA Fully Approves AbbVie's Elahere For Ovarian Cancer

2 years 6 months ago
(RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration has granted full approval for Elahere (mirvetuximab soravtansine-gynx) for the treatment of folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult
RTTNews
Checked
8 minutes 43 seconds ago
This feed is responsible for generating the rss feed related to the topic Markets
Subscribe to Nasdaq Markets feed